PNH in Pregnancy, Contraception & Perioperative Management Protocols
Because the median age at PNH diagnosis is in the late 20s to mid-30s, family planning, contraception safety, and pregnancy management are central clinical questions for women with Paroxysmal Nocturnal Hemoglobinuria.
Similarly, any patient with PNH who requires dental extraction, gallbladder removal, orthopedic surgery, or central venous catheter placement faces an acute surge in complement activation and thrombotic risk that demands a coordinated perioperative protocol.
Before complement inhibitors, pregnancy in PNH carried an 8% to 20% maternal mortality rate and a 4% to 9% fetal mortality rate due to postpartum hepatic and cerebral thrombosis. With terminal C5 inhibition (eculizumab or ravulizumab) plus prophylactic low-molecular-weight heparin (LMWH) throughout gestation and for 6 weeks postpartum, maternal survival exceeds 99% and live birth rates exceed 90%.
How Is Pregnancy Safely Managed in Women With Paroxysmal Nocturnal Hemoglobinuria?
Pregnancy is a potent physiologic Complement-Amplifying Condition (CAC), especially after 20 weeks of gestation, while the first 6 weeks postpartum represent the highest thromboembolic danger window in human physiology. The landmark international registry study by Kelly et al. (NEJM 2015, 75 pregnancies in 61 women) transformed pregnancy from a near-contraindication into a manageable high-risk obstetric pathway:
| Gestational Stage | Complement Inhibitor Regimen | Anticoagulation (LMWH) Rule | Fetal & Maternal Monitoring |
|---|---|---|---|
| Pre-Conception & Contraception | Ensure MenACWY + MenB vaccines are current. Review inhibitor class: Eculizumab (Soliris) has the deepest placental/breast-milk safety data; oral small molecules (iptacopan/danicopan) generally require switching to anti-C5 prior to conception. | Strictly avoid estrogen-containing contraceptives (combined oral pills, patches, rings) due to extreme venous clot risk. Safe options: Levonorgestrel IUD, copper IUD, progestin-only implant/pill, or barrier methods. | Baseline flow cytometry clone size, LDH, CBC, ferritin, folate (5 mg/day), and hepatic/renal baseline panel. |
| 1st & 2nd Trimesters (Weeks 1-26) | Continue standard eculizumab (900 mg IV q14d) or specialist-approved ravulizumab protocol. Eculizumab contains a hybrid IgG2/IgG4 Fc region engineered to minimize transplacental FcRn transport. | Start prophylactic or intermediate-dose low-molecular-weight heparin (LMWH, e.g., enoxaparin) as soon as pregnancy is confirmed if granulocyte clone is >10%-20% or on complement therapy. | Check CBC, reticulocytes, and LDH every 2 to 4 weeks; uterine artery Doppler and serial fetal growth ultrasounds starting at 20 weeks. |
| 3rd Trimester (Weeks 27 to Delivery) | 54% of pregnancies require dose escalation! Expanded maternal plasma volume and placental complement activation cause breakthrough hemolysis in half of patients. Escalate eculizumab to 1,200 mg every 14 days or shorten intervals to every 7-12 days if LDH rises >1.5x ULN. | Maintain daily LMWH; transition to short-acting unfractionated heparin or hold LMWH 24 hours prior to planned induction or neuraxial epidural anesthesia. | Weekly LDH, hemoglobin, platelets, and urinalysis/blood pressure (distinguish PNH breakthrough hemolysis from HELLP syndrome / pre-eclampsia). |
| Delivery & 6 Weeks Postpartum | Administer an extra dose of eculizumab within 24 hours of delivery if surgical blood loss or labor stress occurs. Continue complement inhibition for at least 6-12 weeks postpartum (or lifelong). Eculizumab is not excreted in breast milk; breastfeeding is safe! | Non-negotiable rule: Resume LMWH 6 to 12 hours after vaginal delivery (12-24h after C-section) and continue for a minimum of 6 full weeks postpartum (when 80% of historical maternal PNH clots occurred). | Check cord blood complement if indicated; monitor maternal CBC and LDH at postpartum weeks 1, 3, and 6. |
5 Rules for Safe Surgery, Anesthesia, and Dental Procedures in PNH
Surgical tissue trauma, ischemia-reperfusion, general anesthetics, and postoperative inflammation strongly activate the complement cascade. Every surgeon and anesthesiologist caring for a PNH patient should follow this 5-point checklist:
1. Schedule Surgery Right After Infusions
PEAK DRUG CONCENTRATIONFor elective surgeries, schedule the procedure within 1 to 3 days after a scheduled IV ravulizumab or eculizumab infusion so circulating complement inhibitor concentrations are at their peak. If the patient is in the final week of an 8-week ravulizumab or 2-week eculizumab cycle, advance the infusion to 24-48 hours before surgery.
2. Never Interrupt Oral Proximal Inhibitors
NPO & ORAL CONTINUITYPatients taking oral iptacopan (Fabhalta) or danicopan (Voydeya) must be allowed to take their morning and evening capsules with a small sip of water despite surgical NPO (nothing by mouth) orders. If prolonged postoperative ileus prevents oral intake for >24 hours, bridge immediately with parenteral anti-C5 therapy.
3. Perioperative Hydration & Blood Products
LEUKOREDUCED PRBCSMaintain normothermia (avoid cold operating rooms if cold agglutinins coexist) and generous IV isotonic crystalloid hydration to prevent renal tubular hemoglobin precipitation. If red blood cell transfusion is required, transfuse ABO-compatible, leukoreduced packed red blood cells. Note: If significant intraoperative blood loss (>1.5 L) or plasma exchange occurs, administer a supplemental dose of complement inhibitor immediately post-op.
4. Aggressive Postoperative Thromboprophylaxis
EARLY LMWH + COMPRESSIONApply sequential pneumatic compression devices intraoperatively and initiate pharmacologic thromboprophylaxis with low-molecular-weight heparin (LMWH) as soon as surgical hemostasis is secure (provided platelet count is >50 x 10^9/L). Monitor LDH, hemoglobin, bilirubin, and creatinine daily for 72 hours postoperatively.
Frequently Asked Hematology & Patient Questions
Direct, link-free clinical answers grounded in ASH, IPIG, and Phase 3 complement inhibitor trial evidence.
Does eculizumab (Soliris) cross the placenta or enter breast milk during pregnancy?
In the landmark NEJM study by Kelly et al. (2015), cord blood samples were tested in 20 infants born to mothers receiving eculizumab: the drug was undetectable in 13 samples and present only at trace, non-pharmacologic levels in 7 samples, causing no infant complement depletion or infection problems. Furthermore, eculizumab was not detected in any of the 10 breast milk samples tested, confirming that mothers on eculizumab can safely breastfeed.
Clinical source: Kelly et al., NEJM 2015.
Can a woman with PNH take oraliptacopan (Fabhalta) or pegcetacoplan (Empaveli) during pregnancy?
Because iptacopan and danicopan are small-molecule oral drugs and pegcetacoplan is a PEGylated peptide with limited human pregnancy safety registries compared with eculizumab, current international consensus recommends transitioning women who are planning pregnancy (or who become pregnant) onto eculizumab (or specialist-managed ravulizumab) prior to conception or early in the first trimester.
Clinical source: Brodsky, Blood 2024 · See Complement Inhibitors.
Do I need antibiotic prophylaxis before routine dental cleanings if I have PNH?
If your absolute neutrophil count (ANC) is normal (>1.5 x 10^9/L), routine dental cleanings rarely require special antibiotic prophylaxis beyond standard care. However, if you have AA-PNH overlap with moderate-to-severe neutropenia (ANC < 1.0 x 10^9/L) or are undergoing invasive oral surgery (tooth extraction or root canal), your hematologist will typically prescribe prophylactic amoxicillin/clavulanate and check platelet counts (>50 x 10^9/L) beforehand.
Clinical source: AAMDSIF Dental & Surgical Care Guide.